Sangamo Therapeutics Inc Earnings & Forecasts

SPY—QQQ—BTC/USD—DIA—GLD—TLT—

Premium

Sangamo Therapeutics Inc

SGMOOTC

Trade with Public

$0.0740

-0.10-58.33%

Last update: Jun 23, 3:59 PM

$0.0777

-0.0999-56.25%

Overview NewsEarnings ForecastEvents Price Targets Financials Sentiment Ownership Compare

Sangamo Therapeutics Inc Earnings & Forecasts

Sangamo Therapeutics Inc (SGMO) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

Quarterly Revenue (Billions)

Sangamo Therapeutics Inc Guidance

Sangamo Therapeutics Inc (SGMO) last issued guidance on April 26, 2023 for Q1 2023. The company guided revenue in the range of $158M - $158M for the period.

Recent Earnings Results

Metric	Q1 '26	Q4 '25	Q3 '25	Q2 '25
Earnings Per Share (Non-GAAP)
Estimate	$-0.06	$-0.02	$-0.07	$-0.10
Actual	$-0.08	$-0.11	$-0.11	$-0.08
Surprise	-33.3%	-450.0%	-57.1%	+20.0%
Revenue
Estimate	$28.9M	$38.1M	$40.6M	$27.1M
Actual	$1.4M	$14.2M	$581000	$18.3M
Surprise	-95.0%	-62.8%	-98.6%	-32.4%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q2 '26E	Q3 '26E	Q4 '26E
Earnings Per Share (Non-GAAP)
Consensus	$-0.04	$-0.04	$-0.04
Revenue
Consensus	$6.4M	$6.4M	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
Sangamo Therapeutics Q1 EPS $(0.08) Misses $0.01 Estimate, Sales $1.442M Miss $33.725M Estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $0.01 by 900 percent. This is a 42.86 percent increase over losses of $(0.14) per share

Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

PRO
Sangamo Therapeutics Q4 EPS $(0.11) Misses $(0.06) Estimate, Sales $14.200M Miss $16.475M Estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.06) by 83.33 percent. This is unchanged from the same period last year. The company

Benzinga Newsdesk

Earnings Scheduled For March 30, 2026

Benzinga Insights

PRO
Sangamo Therapeutics Q3 EPS $(0.11) Misses $(0.01) Estimate, Sales $581.000K Miss $34.400M Estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.01) by 1275 percent. This is a 375 percent decrease over earnings of $0.04 per share

Benzinga Newsdesk

Earnings Scheduled For November 6, 2025

Benzinga Insights

Sangamo Therapeutics Inc Earnings & Forecasts

Sangamo Therapeutics Inc (SGMO) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

Quarterly Earnings Surprise Amount

Fiscal Quarter	Date Reported	Actual EPS	Estimated EPS	Surprise %
Q1	May 14, 2026	$-0.08	$-0.06	-33.3 %
Q4	Mar 30, 2026	$-0.11	$-0.02	-450.0 %
Q3	Nov 6, 2025	$-0.11	$-0.07	-57.1 %
Q2	Aug 7, 2025	$-0.08	$-0.10	20.0 %

Quarterly Revenue (Billions)

Quarterly Revenue Surprise Amount

Fiscal Quarter	Date Reported	Actual Revenue	Estimated Revenue	Surprise %
Q1	May 14, 2026	$1.44M	$28.88M	-95.0 %
Q4	Mar 30, 2026	$14.20M	$38.15M	-62.8 %
Q3	Nov 6, 2025	$581.00K	$40.64M	-98.6 %
Q2	Aug 7, 2025	$18.31M	$27.09M	-32.4 %

Sangamo Therapeutics Inc Guidance

Sangamo Therapeutics Inc (SGMO) last issued guidance on April 26, 2023 for Q1 2023. The company guided revenue in the range of $158M - $158M for the period.

Recent Earnings Results

Metric	Q1 '26	Q4 '25	Q3 '25	Q2 '25
Earnings Per Share (Non-GAAP)
Estimate	$-0.06	$-0.02	$-0.07	$-0.10
Actual	$-0.08	$-0.11	$-0.11	$-0.08
Surprise	-33.3%	-450.0%	-57.1%	+20.0%
Revenue
Estimate	$28.9M	$38.1M	$40.6M	$27.1M
Actual	$1.4M	$14.2M	$581000	$18.3M
Surprise	-95.0%	-62.8%	-98.6%	-32.4%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q2 '26E	Q3 '26E	Q4 '26E
Earnings Per Share (Non-GAAP)
Consensus	$-0.04	$-0.04	$-0.04
Revenue
Consensus	$6.4M	$6.4M	—

More with Benzinga EdgeGet Access

Sangamo Therapeutics Inc

Sangamo Therapeutics Inc Earnings & Forecasts

Sangamo Therapeutics Inc Guidance

Recent Earnings Results

Earnings & Guidance News